mda

Muscular Dystrophy Association Launches Nationwide Holiday Retail Campaign, Bringing Support for Families to Communities Across the Country

Annual campaign gives shoppers an opportunity to turn everyday purchases into meaningful impact for people living with muscular dystrophy, ALS and related neuromuscular diseases. NEW YORK – Wednesday, ...
mdaOpinion

ACT for ALS Reauthorization Advances to the President After Today’s Senate Action

The Muscular Dystrophy Association applauds the United States Senate for passing the House’s version of the ACT for ALS ...
mda

Muscular Dystrophy Association Names Jodi Wolff, PhD, Chief Mission Officer

The Chief Mission Officer is a newly created leadership role to strengthen MDA’s mission-driven work across the neuromuscular disease community. Most recently, Dr. Wolff served as founder of Strategic ...
mda

FDA Approves Isembyld (apitegromab-mstn), the First and Only Muscle-Targeted Therapy for Spinal Muscular Atrophy, Marking a New Milestone in SMA Treatment

New York, Friday, September 11, 2026 – The Muscular Dystrophy Association (MDA) marks another milestone for the neuromuscular community with the U.S. Food and Drug Administration (FDA) approval of ...
mda

Statement from the Muscular Dystrophy Association on the FDA Cellular, Tissue, and Gene Therapies Advisory Committee Vote on Deramiocel

Washington, D.C., July 29, 2026 – Today, the U.S. Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee convened to provide advice and expertise on the Biologics ...
mda

MDA Expands 2026 Engage Symposium Series, Bringing the Neuromuscular Community Together in Four U.S. Cities

Free, in-person events unite families, clinicians, researchers, and advocates to accelerate progress, advance care, and strengthen connection across the neuromuscular community. New York, Monday, June ...
mda

FDA Expands Approval of VYVGART and VYVGART Hytrulo to All Adults Living with Generalized Myasthenia Gravis

New York, Friday, May 8, 2026 – The Muscular Dystrophy Association (MDA) today welcomed the U.S. Food and Drug Administration’s (FDA) approval for label expansion of VYVGART® (efgartigimod alfa-fcab) ...
mda

2026 MDA Wings Over Wall Street Gala to Honor Tim Green, Dr. Merit Cudkowicz, and IEX Exchange in the Fight to End ALS

The 26th Annual MDA Wings Over Wall Street Gala to Benefit ALS Research will take place on Thursday, June 4, hosted by Bill Ritter, ABC7 New York Eyewitness News. Dr. Merit Cudkowicz with Tim Green ...
mda

FDA Approves High Dose Regimen of SPINRAZA® for Spinal Muscular Atrophy, Reflecting Progress Made Possible Through Decades of MDA Supported Research

MDA’s research funding for Dr. Adrian Krainer’s research led to the groundbreaking discovery of SPINRAZA®. NEW YORK, Monday, March 30, 2026 – The Muscular Dystrophy Association (MDA) celebrates ...
mda

MDA Atlanta Night of Hope Gala to Honor ALS Advocate Justin Upchurch with Steve Ennis Hope Award

The 19th annual event has raised more than $13 million for ALS research and care. Atlanta, GA, Monday, February 9, 2026 – The Muscular Dystrophy Association (MDA) announced the 19th Annual MDA Atlanta ...
mda

Bipartisan Congressional Action Advances Critical Programs for Rare Neuromuscular Disease Research and Care

Washington, D.C., Tuesday, February 3, 2026 – The Muscular Dystrophy Association (MDA) today applauded the bipartisan passage of the annual federal funding bill that sustains critical investments in ...